An Open-label, Prospective Trial Assessing Positive Detection Accuracy and Detection Latency Measures of the Miniature Ingestible Event Marker Tablet Using the D-Tect Patch in Healthy Subjects and Assessing Detection Latency Measures Using the D-Tect Patch in Subjects With Serious Mental Illness Taking Abilify MyCite Tablet
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar I disorders; Major depressive disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 22 Apr 2024 New trial record